Intra-Cellular Therapies Inc. (ITCI) Given Market Perform Rating at Leerink Swann
Intra-Cellular Therapies Inc. (NASDAQ:ITCI)‘s stock had its “market perform” rating reaffirmed by investment analysts at Leerink Swann in a note issued to investors on Tuesday. They presently have a $12.00 target price on the biopharmaceutical company’s stock. Leerink Swann’s target price would indicate a potential upside of 3.36% from the stock’s previous close.
ITCI has been the topic of a number of other reports. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, May 16th. Cantor Fitzgerald set a $29.00 target price on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, May 11th. BidaskClub cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Friday, July 28th. ValuEngine cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus target price of $24.43.
Shares of Intra-Cellular Therapies (NASDAQ ITCI) traded down 0.09% during midday trading on Tuesday, hitting $11.61. The stock had a trading volume of 324,200 shares. The company’s 50 day moving average price is $11.92 and its 200-day moving average price is $12.51. The firm’s market capitalization is $504.15 million. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $45.20.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.33. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.03 million. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. Intra-Cellular Therapies’s quarterly revenue was down 52.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.71) EPS. Equities analysts predict that Intra-Cellular Therapies will post ($2.57) earnings per share for the current year.
WARNING: “Intra-Cellular Therapies Inc. (ITCI) Given Market Perform Rating at Leerink Swann” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/15/intra-cellular-therapies-inc-itci-given-market-perform-rating-at-leerink-swann.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ITCI. Frontier Capital Management Co. LLC bought a new position in Intra-Cellular Therapies during the fourth quarter valued at $16,605,000. Candriam Luxembourg S.C.A. boosted its position in Intra-Cellular Therapies by 17.2% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 136,200 shares of the biopharmaceutical company’s stock valued at $7,326,000 after buying an additional 20,000 shares in the last quarter. Jennison Associates bought a new position in Intra-Cellular Therapies during the third quarter valued at $16,096,000. EAM Investors LLC boosted its position in Intra-Cellular Therapies by 11.6% in the fourth quarter. EAM Investors LLC now owns 106,243 shares of the biopharmaceutical company’s stock valued at $5,715,000 after buying an additional 11,075 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock valued at $1,431,000 after buying an additional 5,800 shares in the last quarter. 66.66% of the stock is currently owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.